Indefinite Delivery Contract 75N93021D00027

Award Date 9/1/21
Last Date to Order 8/31/28
Ultimate Awardee
Not listed
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an indefinite delivery contract to Leidos, Inc. operating as Saic to provide comprehensive and rapid response services supporting research programs. With a potential value of $545,452,906 over seven years ending August 2028, the multiple award contract vehicle enables delivery orders for clinical trials, manufacturing, animal studies, analytics, storage, and basic research. Leidos was issued an...
The National Institute of Allergy and Infectious Diseases awarded an indefinite delivery contract to FHI Clinical Inc. to provide comprehensive and rapid response research programs. The contract has a potential value of $545,452,906 over a seven-year ordering period through August 2028. Two task orders have been issued against it to date, one for $332,178 and another for $2,000. Under the contract, FHI Clinical Inc. will support the NIAID's mission to conduct biomedical research on infectious,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract titled "Early Phase Clinical Trial Units (EPCTU)" to Icon Government And Public Health Solutions, Inc., a foreign-owned, for-profit organization. The $346.6 million IDIQ will support Phase 0 through Phase II clinical trials of investigational products against infectious diseases over a 10-year...
The National Institute of Allergy and Infectious Diseases awarded an indefinite delivery contract to The Emmes Company LLC on September 1, 2021. With a potential value of $545,452,906 over seven years, this single award IDC supports NIAID's research programs through a broad range of services. Task Order 1 issued under the contract is a firm fixed price order valued at $2,000 to satisfy minimum requirements. Performance will take place in Potomac, MD from September 1, 2021 through August 31,...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to PPD Development LP with a potential value of $545,452,906 to provide comprehensive and rapid response capabilities for research programs through September 2028. Task orders issued against the contract include over $132 million for clinical trial management support services relating to COVID-19, as well as orders valued at $2.33 million, $2 million, and $82.5...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to Lovelace Biomedical Research Institute on September 1, 2021 with a potential value of $545,452,906. Under the terms of the contract, Lovelace Biomedical Research Institute will provide a broad range of services to support biomedical research conducted by NIAID, including clinical trials, manufacturing and controls, nonclinical animal studies, analytics,...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an indefinite-delivery/indefinite-quantity contract to Bioqual, Inc. valued at $545 million with a period of performance from September 2021 to August 2028. Task orders issued against the contract include a $2,000 firm fixed price order to Bioqual for comprehensive and rapid response services in Bethesda, Maryland from September 2021 to August 2022. The original solicitation sought proposals for a...
The National Institute of Allergy and Infectious Diseases awarded a single award Indefinite Delivery Contract to Booz Allen Hamilton Inc. with a potential value of $545,452,906 to provide comprehensive and rapid response services supporting NIAID's research programs through August 2028. A $2,000 firm fixed price delivery order was also awarded against the contract for unspecified Task Area D services in Bethesda, Maryland from September 2021 through August 2022. The original solicitation...
The National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to Mriglobal, doing business as Midwest Research Institute, with a potential value of $545,452,906 and period of performance from September 1, 2021 through August 31, 2028. The contract provides comprehensive and rapid response services to support NIAID's research programs including clinical trials, manufacturing, nonclinical studies, analytics, and basic research. A $2,000 firm fixed...
The National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to Camris International, LLC to support biomedical research programs. The contract vehicle has a potential value of $545,452,906 to be obligated against through task orders over a seven-year ordering period ending August 2028. Two task orders have been awarded to date under the contract: one for $545,232 for current good manufacturing practice process development of a trachoma vaccine in Bethesda,...

Icon Government and Public Health Solutions, Inc. was awarded a multiple award indefinite delivery indefinite quantity contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The master IDIQ, titled "Comprehensive and Rapid Response to NIAID Research Programs," has a potential value of $545 million and period of performance from September 2021 through August 2028.

Under the master IDIQ, Icon received a $2 million delivery order to provide comprehensive and rapid response services supporting NIAID's research programs. This includes clinical trials, manufacturing, nonclinical animal studies, analytics, and basic research. Icon will perform these services from its Bethesda, Maryland location under a firm fixed price arrangement from September 2021 through August 2022.

The original solicitation sought proposals for the "Comprehensive and Rapid Response to NIAID Research Programs" IDIQ to enable NIAID to efficiently address a broad range of biomedical research support needs. This includes expanding knowledge of infectious, immunologic, and allergic diseases, as well as developing domestic and international research capacity. Offerors were required to demonstrate expertise in clinical research, vaccine development, and other areas aligned with NIAID's mission. Proposals were due in July 2020 for a contract with a potential seven-year ordering period.

Generated 1/4/24, 9:21 PM